The All India Institute of Medical Sciences, New Delhi, has transferred an artificial intelligence-based mammography interpretation technology it developed to BPL Medical Technologies, marking a formal step toward moving the tool from academic research into commercial clinical products. The technology transfer ceremony was held at AIIMS Delhi on September 16, bringing together senior figures from both organisations to mark what AIIMS described as an important milestone in translating research into real-world healthcare applications.
What the AI Model Actually Does
The technology is an AI-based mammography interpretation model designed to support radiologists in analysing mammography examinations, with the broader aim of assisting breast-cancer screening and diagnosis workflows. Rather than replacing a radiologist’s judgment, the model is built to function as an interpretive aid, helping flag and analyse findings within mammogram images so a treating radiologist can work through cases more efficiently and with an added layer of computational support.
Why This Matters: India’s Radiologist Shortage
The model’s stated purpose points directly at a persistent structural gap in Indian healthcare: specialist breast-imaging expertise remains limited outside major medical centres, meaning mammograms captured at smaller hospitals or diagnostic centres often lack easy access to a radiologist with deep subspecialty experience in breast imaging specifically. A mammography machine can produce the image, but that image still requires skilled interpretation to be clinically useful, and it’s that interpretation step, not image acquisition itself, where India’s shortage of specialist expertise is most acutely felt in smaller cities and towns.
From Academic Research to Commercial Product
The handover was formalised in the presence of AIIMS Director Dr. Nikhil Tandon and BPL Technologies CFO Ajay Jindal, alongside a broader group from both institutions: AIIMS Associate Dean for Research Govind Makharia, the head of the institute’s Intellectual Property Rights Cell, and radiology department faculty including Professor Smriti Hari and Associate Professor Dr. Krithika Rangarajan, who appear to have led the technology’s development, alongside BPL Medical Technologies CEO Guruswamy Krishnamoorthy.
“This technology transfer demonstrates how research generated within academic institutions can be translated into solutions that address real-world healthcare.”
— Dr. Nikhil Tandon, Director, AIIMS Delhi
Tandon said he hoped the initiative would mark the beginning of similar technology transfers from AIIMS going forward, part of what he described as the institute’s continued emphasis on responsibly translating biomedical research into clinical applications rather than leaving it confined to published papers.
Reaching Tier 2 and Tier 3 India
Under the agreement, BPL Medical Technologies will lead further development, validation, and integration of the AI model directly into mammography equipment, combining AIIMS Delhi’s clinical and academic research with BPL’s manufacturing and medical device development capabilities.
“We are adapting it for mammography equipment and making it accessible even in remote areas.”
— Ajay Jindal, Chief Financial Officer, BPL Medical Technologies
Both organisations flagged tier 2 and tier 3 regions, smaller Indian cities and towns beyond the major metros, as a specific focus for eventual deployment. That geographic framing matters because it’s precisely where the underlying access gap this technology targets is most pronounced: tier 2 and tier 3 centres are more likely to have mammography equipment than a resident radiologist with deep breast-imaging subspecialty training, the exact mismatch an AI interpretation layer built into the equipment itself is intended to help close.
The technology-transfer model itself is also worth noting. Rather than AIIMS commercialising the innovation independently, the institute is licensing it to an established medical device manufacturer already positioned to handle regulatory approval, large-scale production, and distribution across India’s hospital and diagnostic-centre network, a route that mirrors how many academic medical breakthroughs move from a research lab into everyday clinical use elsewhere in the world. AIIMS’s Intellectual Property Rights Cell, whose head was present at the handover, played a central role in structuring that transfer.
Part of a Broader Push for AI-Enabled Preventive Care in India
This transfer lands alongside a broader pattern of AI and technology-driven efforts to expand access to preventive and diagnostic healthcare across India. It echoes the logic behind Philips’ recent AI-enabled preventive diagnostics collaboration with CENT, which similarly aims to bring earlier, more consistent screening capability to a broader population, and sits alongside India’s own national HPV vaccination push against cervical cancer, another cancer-prevention effort built around expanding access beyond India’s major urban health systems. Breast cancer, like cervical cancer, is a disease where earlier detection meaningfully changes treatment outcomes, making tools that extend specialist-level screening support into underserved regions a recurring theme across India’s broader preventive-health strategy this year.
What Comes Next
Neither AIIMS nor BPL has published a specific timeline for when the AI-integrated mammography equipment might reach clinical validation or commercial availability. Jindal noted that AI is becoming an increasingly important part of medical imaging more broadly, and said the technology is expected to shape patient experience by supporting earlier intervention and a smoother diagnostic workflow for radiologists. For now, the transfer marks the starting point of that development process rather than its conclusion, with the real test still ahead: whether the model performs reliably enough across diverse clinical settings, particularly the lower-resource tier 2 and tier 3 centres it’s explicitly designed to serve, to earn the kind of validation needed for widescale clinical deployment.